Evidence map›Paper›PMID 40647406›Full record

ArticleCancers2025

Prognostic Features of Recurrent Midline and H3 K27M-Mutant Glioma.

Stephen J Bagley, Yoshie Umemura, Joe S Mendez, Isabel Arrillaga-Romany, Kevin J Bielamowicz, Nick Butowski, Kelley Hutchins, Xiao-Tang Kong, Yazmin Odia, Akanksha Sharma and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Stephen J BagleyPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Yoshie UmemuraDepartment of Neuro-Oncology, Barrow Neurological Institute, Phoenix, AZ 85013, USA.ORCID 0000-0001-7137-661X
Joe S MendezDepartment of Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Isabel Arrillaga-RomanyDepartment of Neuro-Oncology, Massachusetts General Hospital, Boston, MA 02214, USA.
Kevin J BielamowiczDepartment of Pediatrics, Arkansas Children's Hospital, The University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA.
Nick ButowskiDepartment of Neuro-Oncology, University of California, San Francisco, CA 94143, USA.
Kelley HutchinsDepartment of Hematology/Oncology, Hawaii Pacific Health, Honolulu, HI 96813, USA.
Xiao-Tang KongDepartment of Neurology, University of California Irvine, Irvine, CA 92697, USA.ORCID 0000-0001-9487-6975
Yazmin OdiaMiami Cancer Institute, Miami, FL 33176, USA.ORCID 0000-0003-3602-3899
Akanksha SharmaDepartment of Neuro-Oncology, Saint John's Cancer Institute, Pacific Neuroscience Institute, Santa Monica, CA 90404, USA.
Lauren WeintraubDepartment of Pediatrics, Albany Medical Center, Albany, NY 12208, USA.ORCID 0009-0007-3802-711X
Carl KoschmannDepartment of Pediatric Neuro-Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Center Institute, Boston, MA 02215, USA.
Amanda M SaratsisDepartment of Neurosurgery, Advocate Aurora Healthcare, Chicago, IL 60657, USA.ORCID 0000-0002-4913-2771
Tom BrundageChimerix Inc., A Jazz Pharmaceuticals Company, Durham, NC 27713, USA.
Samuel C RamageChimerix Inc., A Jazz Pharmaceuticals Company, Durham, NC 27713, USA.ORCID 0000-0002-0098-114X
Rohinton S TaraporeChimerix Inc., A Jazz Pharmaceuticals Company, Durham, NC 27713, USA.
Truman KnowlesDepartment of Neuro-Oncology, University of California, San Francisco, CA 94143, USA.ORCID 0009-0002-9501-823X
Dewen YangChimerix Inc., A Jazz Pharmaceuticals Company, Durham, NC 27713, USA.
Joshua E AllenChimerix Inc., A Jazz Pharmaceuticals Company, Durham, NC 27713, USA.
Timothy CloughesyDepartment of Neurology, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0002-8656-7483

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Chimerix (United States) NANCI NIH HHS P50 CA211015
6 · The paper itself

Abstract

High-grade glial tumors represent the most morbid form of brain cancer [...].

Indexed as

diffuse gliomadiffuse midline gliomaH3 K27M

Identifiers

PMID40647406
PMCPMC12248830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.